Demographics and patient characteristics
| Patient characteristics . | Enoxaparin (N = 50), n (%) . | Control (N = 83), n (%) . | P . |
|---|---|---|---|
| Male | 33 (66) | 48 (58) | .37 |
| Age at diagnosis, y (range) | 62 (26-89) | 61 (24-82) | .84 |
| Type of glioma | .18 | ||
| Anaplastic astrocytoma | 5 (10) | 2 (2) | |
| Anaplastic oligodendroglioma | 4 (8) | 10 (12) | |
| Glioblastoma | 41 (82) | 71 (86) | |
| Hypertension | 13 (26) | 41 (49) | .01 |
| Chronic kidney disease | 1 (2) | 2 (2) | 1.00 |
| Glioma treatment | |||
| Involved field radiation | 49 (98) | 82 (99) | 1.00 |
| Stereotactic radiosurgery | 19 (38) | 20 (24) | .12 |
| Surgical resection | 33 (66) | 56 (67) | 1.00 |
| Any antineoplastic drug | 48(96) | 81 (98) | .63 |
| Antiangiogenic agents | 23 (46) | 42 (51) | .72 |
| Aspirin use | 5 (10) | 11 (13) | .78 |
| Patient characteristics . | Enoxaparin (N = 50), n (%) . | Control (N = 83), n (%) . | P . |
|---|---|---|---|
| Male | 33 (66) | 48 (58) | .37 |
| Age at diagnosis, y (range) | 62 (26-89) | 61 (24-82) | .84 |
| Type of glioma | .18 | ||
| Anaplastic astrocytoma | 5 (10) | 2 (2) | |
| Anaplastic oligodendroglioma | 4 (8) | 10 (12) | |
| Glioblastoma | 41 (82) | 71 (86) | |
| Hypertension | 13 (26) | 41 (49) | .01 |
| Chronic kidney disease | 1 (2) | 2 (2) | 1.00 |
| Glioma treatment | |||
| Involved field radiation | 49 (98) | 82 (99) | 1.00 |
| Stereotactic radiosurgery | 19 (38) | 20 (24) | .12 |
| Surgical resection | 33 (66) | 56 (67) | 1.00 |
| Any antineoplastic drug | 48(96) | 81 (98) | .63 |
| Antiangiogenic agents | 23 (46) | 42 (51) | .72 |
| Aspirin use | 5 (10) | 11 (13) | .78 |